287 related articles for article (PubMed ID: 26921205)
1. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.
Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Lonardo A
Adv Ther; 2016 Mar; 33(3):291-319. PubMed ID: 26921205
[TBL] [Abstract][Full Text] [Related]
2. Nuclear receptors and nonalcoholic fatty liver disease.
Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
[TBL] [Abstract][Full Text] [Related]
3. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
Li X; Wang Z; Klaunig JE
Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.
Francque S; Szabo G; Abdelmalek MF; Byrne CD; Cusi K; Dufour JF; Roden M; Sacks F; Tacke F
Nat Rev Gastroenterol Hepatol; 2021 Jan; 18(1):24-39. PubMed ID: 33093663
[TBL] [Abstract][Full Text] [Related]
5. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease.
Pan J; Zhou W; Xu R; Xing L; Ji G; Dang Y
Biomed Pharmacother; 2022 Jul; 151():113127. PubMed ID: 35598367
[TBL] [Abstract][Full Text] [Related]
6. Evolving therapies for non-alcoholic steatohepatitis.
Tilg H; Moschen AR
Expert Opin Drug Discov; 2014 Jun; 9(6):687-96. PubMed ID: 24766298
[TBL] [Abstract][Full Text] [Related]
7. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
8. The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease.
Yang Z; Danzeng A; Liu Q; Zeng C; Xu L; Mo J; Pingcuo C; Wang X; Wang C; Zhang B; Zhang B
Int J Biol Sci; 2024; 20(1):113-126. PubMed ID: 38164174
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.
Fougerat A; Montagner A; Loiseau N; Guillou H; Wahli W
Cells; 2020 Jul; 9(7):. PubMed ID: 32650421
[TBL] [Abstract][Full Text] [Related]
10. [Treatment Options in Non-alcoholic Fatty Liver Disease].
Kim W
Korean J Gastroenterol; 2017 Jun; 69(6):353-358. PubMed ID: 28637104
[TBL] [Abstract][Full Text] [Related]
11. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.
Fuchs CD; Traussnigg SA; Trauner M
Semin Liver Dis; 2016 Feb; 36(1):69-86. PubMed ID: 26870934
[TBL] [Abstract][Full Text] [Related]
12. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.
Puengel T; Liu H; Guillot A; Heymann F; Tacke F; Peiseler M
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269812
[TBL] [Abstract][Full Text] [Related]
13. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
[TBL] [Abstract][Full Text] [Related]
14. Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease.
Kim SG; Kim BK; Kim K; Fang S
Endocrinol Metab (Seoul); 2016 Dec; 31(4):500-504. PubMed ID: 28029021
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH.
Cariello M; Piccinin E; Moschetta A
Cell Mol Gastroenterol Hepatol; 2021; 11(5):1519-1539. PubMed ID: 33545430
[TBL] [Abstract][Full Text] [Related]
16. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
Rotman Y; Sanyal AJ
Gut; 2017 Jan; 66(1):180-190. PubMed ID: 27646933
[TBL] [Abstract][Full Text] [Related]
17. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
18. Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease.
Ni M; Zhang B; Zhao J; Feng Q; Peng J; Hu Y; Zhao Y
Biomed Pharmacother; 2019 May; 113():108778. PubMed ID: 30897538
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
Makri E; Cholongitas E; Tziomalos K
World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
[TBL] [Abstract][Full Text] [Related]
20. PPARs and nonalcoholic fatty liver disease.
Liss KH; Finck BN
Biochimie; 2017 May; 136():65-74. PubMed ID: 27916647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
